Breast CancerPhase 3NCT03252431
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase 3 study testing F-627 and Neulasta in people with Breast Cancer and Neutropenia, run by EVIVE Biotechnology at 1 site in United States.
Trial summary
This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Neutropenia
- What is being tested?
- F-627 and Neulasta
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 393 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Apr 2018to 5 Mar 2020
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
- Females ≥18 years of age.
- Diagnosed with Stage I-III breast cancer.
- Subject is scheduled to undergo 4 cycles of neoadjuvant or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).
- ECOG Performance status of ≤2.
- WBC count ≥4.0 × 109/L, hemoglobin ≥11.5 g/dL and a platelet count ≥150 × 109/L.
- Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [alanine aminotransferase {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total bilirubin]) should be less than 2.5x the upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
- All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.
Who cannot join
- Subject is <18 years of age.
- Disease progression has occurred while receiving a taxane regimen.
- Subject has undergone radiation therapy within 4 weeks of enrollment.
- Subject has undergone bone marrow or stem-cell transplantation.
- Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
- Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.
Show all 21Show fewer
- Subject has had chemotherapy within 180 days of screening.
- Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, electrocardiogram (ECG) test, or any other relevant test.
- History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
- Unwillingness to participate in the study.
- Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
- Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.
- Any condition, which can cause splenomegaly.
- Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
- ALT, AST, alkaline phosphatase, total bilirubin ≥2.5x ULN.
- Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
- Women who are pregnant or breast-feeding.
- Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
- Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
- Subjects with Sickle Cell disease
- Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC)
Los Angeles, California, 90095
About this study
Official title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.
Read the detailed description
This is a Phase III, global, two arm, open label clinical study will randomize approximately 400 female subjects (approximately 200 per arm) with Stage I - III invasive breast cancer who are to receive neoadjuvant or adjuvant myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide, 75 and 600 mg/m2, respectively). Subjects in this study will be those who are scheduled to undergo at least four 21-day cycles of chemotherapy treatment. Subjects may be scheduled for more than 4 cycles of chemotherapy; however, study participation will be limited to a subject's first 4 cycles.
The primary objective of this study will be to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC <0.5 x 10^9/L) observed in chemotherapy cycle 1.
Approximately 24 hours after chemotherapy completion in each cycle (Day 2 of the cycle), subjects will receive one of the following treatments:
Arm 1: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
Arm 2: 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Randomization will occur in an equal ratio (1:1) using a central randomization system (IWRS) on Day 1 of the study, the day of chemotherapy administration for the first chemotherapy cycle.
This study is open-label, however, study drug injections are to be administered separately by qualified study personnel to allow study investigators to remain blinded and perform study assessments without knowledge of treatment assignment.
- Conditions
- Breast Cancer, Neutropenia
- Being tested
- F-627, Neulasta
- Medical subject headings
- Breast Neoplasms, Neutropenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
F-627Drug
single dose pre-filled syringe
NeulastaDrug
Also called pegfilgrastim
single dose pre-filled syringe
| Study group | Role | What they receive |
|---|---|---|
| F-627 | Experimental | F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles. Receives: Drug: F-627 |
| Neulasta | Active comparator | 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Receives: Drug: Neulasta |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1
Eligible subjects were randomized in a 1:1 ratio. Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. Subjects remained in their assigned treatment arm throughout the study. Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles). Grade 4 (severe) neutropenia was defined as ANC <0.5 × 109/L within the first 12 days of chemotherapy.
Measured: The first of 4, 21-day chemotherapy cycles (average 3 weeks)
Secondary outcomes (6)
Duration in Days of Use of Intravenous Antibiotic
The duration of use of IV antibiotics was defined as the number of days in which IV antibiotics were administered
Measured: across all 4 chemotherapy cycles (average 84 days)
Duration in Days of Hospitalization
The duration in days of patients been hospitalized for febrile neutropenia (FN) or any infection. Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of >38.0°C (100.4°F) sustained for >1 hour and ANC <0.5 x 10^9/L on the same day.
Measured: across all 4 chemotherapy cycles (average 84 days)
The Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 1
The number of participants with grade 4 neutropenia for chemotherapy cycle 1. Grade 4 (severe) neutropenia was defined as ANC <0.5 × 109/L within the first 12 days of chemotherapy.
Measured: The first of 4, 21-day chemotherapy cycles (average 3 weeks)
The Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.
The number of participants with febrile neutropenia, considering all chemotherapy cycles.
Measured: across all 4 chemotherapy cycles (average 84 days)
The Number of Participants With Use of IV Antibiotics Considering All Chemotherapy Cycles.
The number of participants with use of IV antibiotics, considering all chemotherapy cycles.
Measured: across all 4 chemotherapy cycles (average 84 days)
The Number of Participants in Hospitalization for Febrile Neutropenia or Any Infection Considering All Chemotherapy Cycles
The number of participants in hospitalization for febrile neutropenia or any infection, .
Measured: across all 4 chemotherapy cycles (average 84 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2017
- Study start12 Apr 2018
- Primary completion25 Sep 2019
- Study completion5 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 393 participants (actual)
Sponsor and investigators
- Lead sponsor
- EVIVE Biotechnology
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- John Glaspy, MD, Principal investigator, University of California at Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03252431
- Sponsor's protocol ID
- GC-627-05
- Status last verified
- Apr 2021
- First submitted
- 14 Aug 2017
- Last updated
- 3 Jul 2023
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No